It's smart to know what others have experienced with AROMASIN.
Medicines can have benefits and side effects. It's good for you and your doctor to think about both when deciding on a treatment plan. Below are some of the most common side effects women had during the AROMASIN® (exemestane tablets) IES study. Side effects were usually mild to moderate. Below you can find ways to help manage some of the common side effects. Always report new or different side effects to your doctor right away to be sure they are not a sign of something more serious.
Click the arrow next to each side effect for tips on managing it.
Your bones and AROMASIN
Many women who are past menopause think about their bone health. So you should know that AROMASIN may reduce your bone mineral density (BMD) over time. The lower your BMD, the greater your risk of osteoporosis and fracture could be.
Some women who took part in the AROMASIN IES study developed osteoporosis (4.6% on AROMASIN vs 2.8% on tamoxifen). There was also a risk of fractures (4.2% on AROMASIN vs 3.1% on tamoxifen). This difference was not statistically significant.
AROMASIN® (exemestane tablets) is a prescription medicine for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer. Treatment with AROMASIN should begin after 2 to 3 years of tamoxifen, at which time tamoxifen should be discontinued. Treatment with AROMASIN should continue for 2 to 3 years (until the completion of a total of 5 years of adjuvant treatment with tamoxifen and AROMASIN).
AOU00471
